Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.47 |
| ▸ | HTR2C | P28335 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216938 | 0.90 | HTR2A (0.55) | HTR2AHTR2CKCNH2DRD2CA1 | |
| SCHEMBL5245186 | 0.86 | HTR2A (0.51) | HTR2AHTR2CKCNH2DRD2CA1 | |
| SCHEMBL6102566 | 0.82 | HTR2A (0.44) | HTR2AHTR2CKCNH2DRD2RORC | |
| SCHEMBL5209103 | 0.81 | HTR2A (0.59) | HTR2AHTR2CKCNH2DRD2CA1 | |
| SCHEMBL5212366 | 0.79 | HTR2A (0.54) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5213238 | 0.77 | HTR2A (0.56) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5210470 | 0.75 | HTR2A (0.80) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL27646003 | 0.75 | HTR2A (0.53) | HTR2AHTR2CKCNH2DRD2OPRM1 | |
| SCHEMBL5210197 | 0.72 | HTR2A (0.61) | HTR2AHTR2CKCNH2DRD2CA1 | |
| SCHEMBL5211501 | 0.71 | HTR2A (0.63) | HTR2AHTR2CKCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211735-A1 | 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | MERCK SHARP & DOHME LTD. (GB) | 2006-09-21 | — | — | US | claimed |
| EP-1641756-B1 | 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR | MERCK SHARP & DOHME (GB) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211735-A1 | 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | HTR2A, HTR2C, HTR5A | HTR2A 1/4885HTR2C 2/4885KCNH2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.